Hims, Inc. manufactures men's wellness products. It offers products, including hair loss prevention medicines, sexual wellness products, skincare products, and oral care products.
Hims & Hers Health stock last closed at $53.96, down 2.77% from the previous day, and has increased 231.45% in one year. It has overperformed other stocks in the Household & Personal Products industry by 2.45 percentage points. Hims & Hers Health stock is currently +243.04% from its 52-week low of $15.73, and -26.06% from its 52-week high of $72.98.
As of Sep 15, 2025, there are 226.02M shares of HIMS outstanding. The market value of HIMS is $12.20B. In the last 24 hours, 25.53M HIMS shares were traded.
You need an online brokerage account in order to access the NYSE market and buy HIMS shares.
In our opinion, eToro is the best place to buy stocks. Here's why:
Get $10 towards your share purchase by creating an account with eToro now. This offer is only for US users.
Open eToro AccountNow that you've chosen the best brokerage, it's time to fill out some personal information so you can invest in HIMS today.
Now that you have opened your account on the best stock trading app, your next step is to transfer the money for your investment:
Watch this video walkthrough to see the process of transferring funds into your new brokerage account.
Once you have figured out the best place to buy Hims & Hers Health stock, it's absolutely critical to analyze their stock before you buy, so you actually understand the risk and opportunity.
WallStreetZen was built to help part-time investors perform better fundamental analysis in minutes instead of hours.
You can see all of the due diligence checks on HIMS's stock page.
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge HIMS's fair value.
Using relative valuations methods:
You can access more valuation research on HIMS's stock here.
Out of 8 Wall Street analysts who track HIMS, the consensus analyst rating on Hims & Hers Health is a Hold
It's important to keep in mind that analyst ratings are not recommendations, nor are they investment advice.
Daniel Grosslight, a bottom 4% analyst from Citigroup maintains HIMS with a strong sell rating and raises their HIMS price target from $25.00 to $30.00, on May 6, 2025.
Citigroup's Daniel Grosslight raised their price target on Hims & Hers Health (NYSE: HIMS) by 20% from $25 to $30 on 2025/05/06. The analyst maintained their Strong Sell rating on the stock.
Hims & Hers Health reported its Q1 2024 earnings.
The quarter was "a bit of a Rorschach test," Grosslight said, because "bulls will point to the significant outperformance driven by a GLP-1 induced increase in revenue that offset somewhat below consensus net subscriber adds
Conversely, the analyst said they expect bears will respond by pointing out that management's "lackluster" Q2 guidance places a hefty sales burden on 2H 2025 as incremental margins are declining.
Grosslight said they are "somewhere in the middle, between the bulls and the bears."
For Q1 2025, Hims & Hers Health reported:
Management guided:
For Q2 2025:
For FY 2025:
Co-founder & CEO Andrew Dudum commented: “We’re starting 2025 with incredible momentum.
“Millions of people are turning to us for access to care that is personal, affordable, and has the potential to drive better outcomes.
“We’re building a platform that puts the individual at the center of every decision, and others are taking notice.
“Over time, we expect wider collaboration across the industry, inclusive of pharmaceutical players, innovative leaders in diagnostic and preventative testing, and world-class providers.
“We believe this will strengthen our ecosystem and position us to curate a best-in-class offering that can reach tens of millions of people.
“This is the future of our platform, allowing a historically disjointed industry to reach more consumers, for the benefit of those consumers.”
Allen Lutz, a bottom 10% analyst from Bank of America maintains HIMS with a sell rating and raises their HIMS price target from $22.00 to $26.00, on Apr 29, 2025.
Jonna Kim, a top 34% analyst from TD Cowen downgrades HIMS to a hold rating and lowers their HIMS price target from $44.00 to $30.00, on Apr 29, 2025.
You can dive deeper into what analysts are projecting on the Hims & Hers Health stock forecast page.
Last year, HIMS earnings were $193.60M. Over the past one years, HIMS's earnings have gone up by 987.5% per year. This was faster than the Household & Personal Products industry average of 18.32%.
Last year, HIMS revenue was $2.01B. In the past five year, HIMS's revenue has grown by 68.43% per year. This was faster than the Household & Personal Products industry average of 4.61%.
Dive into HIMS's earnings and revenue performance here.
In the last 12 months, executives and large shareholders at HIMS have sold more shares than they have bought.
Oluyemi Okupe, Chief Financial Officer of HIMS, was the latest HIMS insider to buy. They bought $58,020.81 worth of HIMS shares on Aug 26, 2025.
Research more about who owns HIMS shares here.
No, Hims & Hers Health doesn't provide an income stream by paying out dividends.
One of the biggest reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to see what other community members have to say.
There are two main types of orders:
Hit the Open button and eToro will execute the order.
If you want more help with investing in stocks on eToro, watch the how to video below:
Now that you own some HIMS stock, you'll want to stay up-to-date on your investment.
Create a watchlist to track the most important metrics related to your HIMS stock.
To reiterate, here are the 6 steps to buy stock in Hims & Hers Health:
If you require a place to buy stocks, eToro is our recommended option.
Get Started with eToro TodayIf you want to monitor your new investment in Hims & Hers Health, create a watchlist on WallStreetZen today.